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STRUCTURAL BIOLOGY

Structure of the Wilson disease copper
transporter ATP7B
Ryan M. Bitter1,2†, SeCheol Oh3†, Zengqin Deng1,2, Suhaila Rahman1,2,
Richard K. Hite3*, Peng Yuan1,2*
ATP7A and ATP7B, two homologous copper-transporting P1B-type ATPases, play crucial roles in cellular copper
homeostasis, and mutations cause Menkes and Wilson diseases, respectively. ATP7A/B contains a P-type ATPase
core consisting of a membrane transport domain and three cytoplasmic domains, the A, P, and N domains, and a
unique amino terminus comprising six consecutive metal-binding domains. Here, we present a cryo–electron
microscopy structure of frog ATP7B in a copper-free state. Interacting with both the A and P domains, the metal-
binding domains are poised to exert copper-dependent regulation of ATP hydrolysis coupled to transmembrane
copper transport. A ring of negatively charged residues lines the cytoplasmic copper entrance that is presumably
gated by a conserved basic residue sitting at the center. Within the membrane, a network of copper-coordinating
ligands delineates a stepwise copper transport pathway. This work provides the first glimpse into the structure and function of ATP7 proteins and facilitates understanding of disease mechanisms and development of
rational therapies.

Ubiquitously found in all kingdoms of life, P-type adenosine triphosphatases (ATPases) use adenosine 5′-triphosphate (ATP) hydrolysis to actively pump substrates across cell membranes (1). In
humans, two Cu+-transporting P-type ATPases, ATP7A and ATP7B,
are key players in maintaining cellular copper homeostasis (2–4).
Dysregulation of cellular copper levels is deleterious, as copper functions as an essential cofactor for numerous enzymes, while excess
copper is cytotoxic (2–4). Human ATP7A and ATP7B, which share
56% sequence identity, differ in tissue expression, cellular trafficking, and physiological functions (2–4). ATP7A is important for
copper uptake in the intestine, and dysfunction causes Menkes
disease characterized by systemic copper deficit (5, 6). By contrast,
ATP7B is most abundantly expressed in hepatocytes to excrete excess copper into bile, and consequently, missense mutations give rise
to Wilson disease that is represented by hepatic copper overload
and toxicity (7, 8).
The P-type ATPases, which constitute a large superfamily of
membrane pumps that catalyze the transmembrane transport of diverse substrates, all contain a common structural core composed of
a transmembrane domain (TMD), an actuator (A) domain, a phosphorylation (P) domain, and a nucleotide-binding (N) domain (1).
Substrate transport is actively driven by conformational changes
associated with phosphorylation and dephosphorylation of a conserved aspartate residue in the P domain, which result in alternating
access of substrate binding sites in the TMD within the membrane
(1). The stepwise transport process is described by the Post-Albers
cycle with distinct functional states, including high-affinity E1 and
low-affinity E2 states for substrate as well as phosphoenzyme intermediate states E1P and E2P (9, 10).
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ATP7A and ATP7B belong to the prevalent P1B subfamily of
heavy metal–transporting ATPases that are widespread in both prokaryotes and eukaryotes (11). Crystal structures of a prokaryotic
homolog from Legionella pneumophila, LpCopA, have delineated
the core structure of a P1B ATPase and suggested a potential Cu+
transport pathway across cell membranes (12, 13). The structure
and ion permeation mechanism appear to differ substantially from
those of the prototypical P2 ATPase subfamily exemplified by the
best characterized sarcoplasmic reticulum Ca2+-ATPase (SERCA1a)
(14–17). The LpCopA TMD has two additional P1B-specific transmembrane helices, a long and curved MA helix and a kinked MB
helix with an amphipathic helical segment at the cytoplasmic membrane interface, that are not present in the canonical SERCA1a
(12, 13). In addition to the common P-type ATPase core pieces
comprising the TMD and A, P, and N domains, P1B-ATPases contain one or multiple metal-binding domains (MBDs) in the N terminus (11, 18, 19). The prokaryotic LpCopA acquires a single MBD,
which was not resolved in the crystal structures (12, 13). The N terminus is elaborated in higher eukaryotic Cu+-ATPases, which contain six consecutive MBDs (MBD1 to MBD6) that receive Cu+ from
a cytoplasmic Cu+ chaperone antioxidant protein 1 (ATOX1) and
participate in subsequent Cu+ transport across the membrane (19–24).
While MBD1 to MBD4 are not strictly required and appear to play
a regulatory role, either MBD5 or MBD6 is necessary for Cu+ transport (25–27). ATP7A/B additionally contains a conserved C-terminal
region absent in LpCopA that appears to communicate with the
N-terminal domains to regulate copper-stimulated trafficking (28).
These extra segments at both the N and C termini render ATP7A/B
much larger in size than the prokaryotic counterparts and confer
sophisticated Cu+-dependent regulation mechanisms of protein
targeting, cellular trafficking, and post-translational modification
(25–28), which remain poorly understood.
To better understand the unique features and physiological and
pathological properties of ATP7 proteins, here, we describe a cryo–
electron microscopy (cryo-EM) structure of ATP7B from Xenopus
tropicalis determined at an overall resolution of ~3.2 Å. The structure
reveals a conserved Cu+-ATPase core surrounded by the N-terminal
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MBDs and the C-terminal regulatory domain and delineates a
plausible Cu+ transport pathway lined by a network of amino acids
serving as Cu+ ligands in the membrane. Meanwhile, the first atomic
model of a vertebrate Cu+-ATPase provides a molecular blueprint
for understanding hundreds of missense mutations associated with
devastating Menkes and Wilson diseases and facilitates rational
design of therapeutic interventions.
RESULTS

Structure determination
We expressed and purified the full-length X. tropicalis ATP7B protein consisting of 1467 amino acids, which shares 67% sequence
identity with the human ortholog (fig. S1). We observed protein
degradation likely owing to the flexible linkage of the six N-terminal
MBDs. Nuclear magnetic resonance (NMR) spectroscopy studies
have indicated that the individual MBDs are loosely connected like
beads on a string except for MBD5 and MBD6 forming a compact

B

2 3 6

A

N

C

P

MA MB M1 M2 M3 M4 M5

M6

C

10

Downloaded from https://www.science.org at Washington University on June 05, 2022

1 4 5

ATP turnover rate (min−1)

AN

unit preceding the first TM helix (21, 22, 29). Thus, for structural
studies, we removed the first four of six MBD domains (MBD1 to
MBD4) that are not essential for Cu+ transport (25–27, 30). The
truncated construct, which we termed xATP7BEM, consists of amino
acids 481 to 1467 with intact MBD5 and MBD6 and C terminus. The
resulting construct has a predicted molecular weight of ~107 kDa
(Fig. 1A). Consistent with previous studies (25–27), purified
xATP7BEM lacking MBD1 to MBD4 retains ATPase activity (Fig. 1B).
Furthermore, the ATP turnover rate of xATP7BEM (7.8 min−1) is
higher than that of the full length (3.4 min−1) (Fig. 1B). This observation supports the notion that MBD1 to MBD4 negatively regulate
ATPase activity before stimulation by cytoplasmic Cu+ chaperone
ATOX1 (31).
We purified xATP7BEM to homogeneity and determined the
cryo-EM structure at an overall resolution of ~3.2 Å (Fig. 1C, fig. S2,
and table S1). The cryo-EM densities are of high quality for the
TMD and A and P domains, allowing unambiguous model building
(Fig. 1C and fig. S3). The densities were less well resolved for the
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Fig. 1. Cryo-EM structure of xATP7B. (A) Membrane topology and domain organization of ATP7B. ATP7B contains six N-terminal MBDs (orange), a TMD with eight TM
helices (cyan and green), and four cytoplasmic domains including A (yellow), P (blue), N (magenta), and C-terminal (red) domains. The MBD1 to MBD4 deletion construct
used for cryo-EM analysis is indicated by a pair of scissors. The cyan lines mark the approximate membrane boundaries. (B) ATP turnover rates for the full-length wild type
(WT; 3.4 ± 0.1 min−1), xATP7BEM (7.8 ± 0.5 min−1), and C-terminal deletion (xATP7B C) using the inactive mutant (D1024A) as the baseline for subtraction. Data are
means ± SD (three independent measurements). For comparison, the maximum turnover rate of LpCopA was ~11.7 min−1 (12). (C) Cryo-EM density map. The TMD,
cytoplasmic domains (MBD5 and MBD6, CTD, and A, P, and N domains), and the MBD6-TMD linker are indicated. (D) Structure of xATP7BEM. The TM helices (MA, MB, and
M1 to M6) and cytoplasmic domains are indicated.
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cytoplasmic N domain, and thus the crystal structure of the prokaryotic
LpCopA [Protein Data Bank identification (PDB ID): 3RFU] was
used to guide model building in this region (12). Three-dimensional
variability analysis (3DVA) revealed that the densities corresponding
to MBD5 to MBD6, which were relatively weak in the consensus
reconstruction, were present in only a subset of the particles. After 3D
classification, we obtained two subsets, one in which MBD5 and
MBD6 were ordered (state 1) and one in which the MBD5 and MBD6
densities were absent (state 2). To model MBD5 and MBD6, we
docked the crystal structure of the isolated human MBD4 (PDB ID:
6A71) into the state 1 density map and then manually adjusted (32).
Assignment of MBD5 and MBD6 was further corroborated by the
visible densities for the MBD5-MBD6 and MBD6-MA linkers (Fig. 1C).
The final atomic model, which was refined to good stereochemistry, fits
well into the density maps (Fig. 1, C and D, fig. S3, and table S1).
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Overall structure of ATP7B
The xATP7BEM structure was determined in the presence of Mg2+
and AlF4− and in the absence of the substrate ions (Cu+), thus
presumably representing an occluded, Cu+-released E2-Pi transition
state in the Post-Albers cycle. Mg2+ and AlF4− are bound at the
conserved phosphorylation site constituted by the invariant “DKTG”
motif from the P domain and the “TGE” loop from the A domain
(fig. S4A), which is analogous to the observation in the crystal structure of LpCopA captured in the E2-Pi state (12). The assignment of
the functional state is further supported by the global structural
agreement between xATP7BEM and LpCopA (fig. S4B) (12).
The TMD comprises eight TM helices that closely resemble those
of LpCopA, including the two P1B-specific helices (MA and MB)
preceding the canonical six TM helices (M1 to M6) shared by P-type

ATPases (Fig. 1, C and D). The first TM helix, MA, is connected to
MBD6 via a partially ordered linker that is ~20 Å in length. The MB
helix contains a sharp kink, enabled by two consecutive glycine residues that are conserved among Cu+-ATPases (fig. S1). Consequently,
the second helical segment in MB runs approximately parallel to the
membrane. A short linker follows MB and connects to the common
core architecture of a P-type ATPase, which sequentially consists of
M1, M2, the A domain, M3, M4, the P and N domains, M5, and M6.
Unique to eukaryotic Cu+-ATPases, the cytoplasmic N terminus
contains six MBDs, which confer exquisite regulation mechanisms
(19). The cryo-EM structure reveals that the last two MBDs (MBD5
and MBD6) are distantly positioned from the lipid bilayer and pack
against both the A and P domains in one state and uncoupled from
the transporter in the other (Fig. 1, C and D, and fig. S2). The locations of MBD5 and MBD6, clearly resolved in the density map of
state 1, differ substantially from the previously suggested positions of
the single N-terminal MBD in LpCopA (12, 33). In addition, in contrast to LpCopA, eukaryotic ATP7 transporters contain a C-terminal
tail following the TMD, which comprises ~90 amino acids. In the
xATP7BEM structure, the C terminus emerging from M6 wraps around
the P domain and reaches MBD5 (Fig. 1, C and D), thus forming an
integral structural unit specific for eukaryotic ATP7 proteins. Together,
it appears that both the extra N- and C-terminal regions constitute
peripheral structural domains that surround the P and A domains,
presumably providing further regulatory mechanisms through direct interdomain interactions (Fig. 1D).
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that the Cu+ entryway is most likely constituted by the cytoplasmic
interface created by MA, MB, and M2 (Figs. 1, C and D, and 2A),
which aligns with the proposed entry site of LpCopA (12, 13). The
Cu+-free structure, together with the distal placement of MBD5 and
MBD6 above the lipid bilayer, prevents visualization of how Cu+ is
transferred from the MBDs to the membrane entrance. Notably, the
poorly ordered linker connecting MBD6 and MA (Fig. 1C) makes
no contacts with other cytoplasmic domains. Together with the
MBDs being disordered in state 2, it appears that the flexible linker
may allow the long-range movement of MBDs necessary for Cu+
delivery to this entry site.
To illuminate the potential Cu+ transport pathway across the
membrane, we mapped the conserved Cu+-binding residues, including cysteine, methionine, and histidine as well as charged amino
acids in the transmembrane region (Fig. 2A). These residues delineate
a virtually complete route allowing Cu+ movement across the lipid
A

bilayer from the cytoplasmic entry to the luminal exit. The presumed
cytoplasmic Cu+ entry site comprises multiple conserved charged
residues (Fig. 2B). A ring of negatively charged residues, including
E643, D727, E778, and D915, appears to form a cation-binding site.
Notably, two conserved histidine residues in the vicinity, H721 and
H779, likely facilitate Cu+ entry by serving as additional Cu+ ligands.
In the absence of Cu+ ions, a conserved arginine residue, R775,
occupies the center of the acidic ring and seals the cytoplasmic side
of the entryway. The negative electrostatic potential of the acidic
ring is partially balanced by nearby lysine residues K717 and K782.
Therefore, Cu+ entering this acidic binding site would likely displace
the side chain of R775, which appears to be critical in stabilizing the
occluded-to-the-cytoplasm conformation and thus functions as a
cytoplasmic gate facilitating Cu+ occlusion. Consistent with this
proposed role of R775, a single missense mutation of the corresponding residue in human ATP7B (R778L) represents one of the most
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Fig. 3. CTD and the N-terminal MBDs. (A) Overall structure highlighting positions of the CTD and the N-terminal MBD5 and MBD6. AlF4− bound in the P domain and the
presumed Cu+-binding motifs in MBD5 and MBD6 are highlighted. (B) MBD5 interacts with both the A and P domains and contacts the CTD. (C) Interface between MBD6
and the A domain. (D) Orthogonal view as in (A) to illustrate domain organization of MBD5 and MBD6, CTD, and the A and P domains. (E) The  helix in the C-terminal tail
CTD interacts with the P domain. (F) The C-terminal  strand CTD extends the  sheet of the P domain. (G) ATP turnover rates for xATP7BEM and mutants weakening interdomain interactions. Data are means ± SD (three independent measurements).
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N-terminal MBDs
Cu+-ATPases from different organisms share the core catalytic
pieces but have a varying number of MBDs in the N terminus (11).
The prokaryotic Cu+-ATPases contain a single MBD, and the lower
eukaryotic ones have two or four, whereas the higher eukaryotic
transporters comprise six consecutive MBDs. NMR studies of individual MBDs have revealed a conserved ferredoxin-like  fold
consisting of ~70 amino acids with an invariant “MxCxxC” Cu+-binding
motif (11, 21, 41–43). The ATP7 transporters engage the MBDs to
receive Cu+ ions from cytosolic Cu+ chaperones such as ATOX1,
which shares the same  structural fold, and to relay Cu+ ions
to the intramembranous transport pathway (19–24). However, the
overall structural arrangement of the MBDs in the intact transporters
and the mechanisms of Cu+ delivery and Cu+-dependent regulation
of transport activity via these MBDs remain unknown. Mutagenesis
studies of ATP7B have demonstrated that either MBD5 or MBD6,
but not MBD1 to MBD4, is required for Cu+ transport activity (25–27),
suggesting that MBD1 to MBD4 play a regulatory role, whereas
MBD5 or MBD6 is essential for Cu+ relay to the membrane entry
site. Consistently, purified xATP7BEM lacking MBD1 to MBD4
showed increased ATPase activity compared with the full-length
enzyme (Fig. 1B).
In the xATP7BEM structure, MBD5 simultaneously contacts the
A, P, and C-terminal domains (Fig. 3A). Notably, the Cu+-binding
motif, which consists of M494, C496, and C499, is precisely located
at the multidomain junction (Fig. 3B). In the vicinity of the Cu+-
binding site, MBD5 and the A and P domains are held together by a
hydrophobic interface comprising I497 and L520 of MBD5, V861
Bitter et al., Sci. Adv. 8, eabl5508 (2022)
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and I870 of the A domain, and L1250 of the P domain. In addition,
E526 of MBD5 and R824 of the A domain form salt bridges. In contrast to MBD5 making extensive interdomain interactions, MBD6
appears to be rather detached from the core pieces, only contacting
the A domain via salt bridge interactions involving R613, E815, and
D826 (Fig. 3, C and D).
In the P-type ATPases, conformational changes in the cytoplasmic domains (A, P, and N domains) driven by ATP hydrolysis are
coupled with ion movement in the TMD (1). In the cryo-EM structure, MBD5 interacts with multiple cytoplasmic domains via its
Cu+-binding motif and nearby residues. This observation indicates
that MBD5 could engage Cu+-dependent regulation of structural
rearrangements of the cytoplasmic domains and, consequently, Cu+
movement in the TMD. Both Cu+-binding motifs in MBD5 and
MBD6 are distant from the cytoplasmic Cu+ entry point as estimated
by the C-C distances between R775 and C496 (~50 Å) and
between R775 and C572 (~56 Å). Therefore, if MBD5 or MBD6
participates in delivering Cu+ to the membrane entry site, long-range
domain movements in MBD5 or MBD6 are expected to occur.
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prevalent of the more than 700 Wilson disease mutations that have
been identified (8, 34).
M726, immediately beneath R775 in the proposed transport
pathway, demarcates the cytoplasmic and intramembranous binding sites and may facilitate Cu+ movement further into the lipid
bilayer (Fig. 2). In the cryo-EM structure, the C-C distances
between M726 in M1 and cysteine residues (C980 and C982) in the
invariant “CPC” motif in M4 are ~10 Å. Presumably, conformational changes in M1 and M4 associated with ATP hydrolysis could
bring M726, C980, and C982 together to bind Cu+ through Cu-S
coordination with trigonal geometry that is selective for Cu+ over
Cu2+ ions (35–37). A network of Cu+-binding residues, including
M1365, M766, D762, M665, M1360, and M668, lines the transmembrane ion path reaching the luminal side. These Cu+ ligands
seem to be meticulously arranged to relay the bound Cu+ ions through
a series of ligand exchange reactions to deliver Cu+ to the lumen. An
analogous mechanism of Cu+ translocation has been suggested for
the structurally unrelated CusA heavy metal efflux pump, in which
a network of methionine residues lines the transmembrane path
(38, 39). Estimation of the water-accessible pore dimension in the
transmembrane region indicates that the permeation pathway below
the CPC site is sufficiently wide for Cu+ conduction (Fig. 2B) (40).
In addition, the negative electrostatic potential on the luminal side
may contribute to the directionality of Cu+ movement to the lumen
through electrostatic attraction (Fig. 2B). These analyses indicate
that the xATP7BEM structure in the E2-Pi conformational state is
occluded to the cytoplasm but open to the lumen, consistent with
an open ion-release pathway suggested by crystal structures and
molecular dynamics simulations of LpCopA in the E2P and E2-Pi
states (12, 13).

SCIENCE ADVANCES | RESEARCH ARTICLE
C-terminal tail
Following the TMD, the eukaryotic ATP7 transporters contain a
C-terminal tail that is absent in prokaryotic homologs (fig. S1). The
C-terminal tail forms intimate interactions with the P domain (Fig. 3,
D and E). The short C-terminal helix CTD makes multiple contacts
with the P domain (Fig. 3E). Furthermore, the C-terminal tail donates
an extra  strand (CTD) that complements the  sheet of the P domain
(Fig. 3F). In addition, the distal C terminus continues toward the
N-terminal MBD5, joining the multidomain interface involving
A

MBD5 and the A and P domains (Fig. 3F). Together, the C-terminal
tail appears to be an integral structural component extending the
cytoplasmic headpieces. Presumably, the C-terminal tail could impart
additional regulatory roles specific for the eukaryotic Cu+-ATPases
through direct interactions with MBD5 and the P domain.
Yeast complementation assays with ATP7B have demonstrated
that the C terminus is critical for function and communicates with the
N terminus as assessed by phosphoproteomics studies (28, 44), in which
Cu+ binding at the N terminus resulted in hyperphosphorylation
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Wilson disease mutations
Our cryo-EM structure provides a molecular blueprint for understanding Wilson disease mutations. We mapped known missense
human mutations of Wilson disease onto the cryo-EM structure of
frog ATP7B and labeled these disease mutations according to the
human ATP7B sequence for consistency with the Wilson disease
database (Fig. 4) (48). Most of the known disease mutations are located
within the structurally resolved region of the full-length protein,
including the TMD and cytosolic A, P, and N domains. This reinforces
the engagement of each of these domains during the transport cycle
driven by ATP hydrolysis. Notably, several mutations occur in structural elements located at the N-terminal MBDs and the obligatory
C-terminal tail that interact with the cytosolic headpieces. In particular, the human mutation R616Q/W (corresponding to R613 in frog
ATP7B) would disrupt salt bridge interactions between MBD6
and the A domain (Fig. 3C). Another disease mutation Q1399R
(equivalent to Q1405 in frog ATP7B) is located at the interface
between the C-terminal tail and the P domain. These observations
further strengthen the critical roles of these peripheral regulatory
components.
DISCUSSION

This work now reveals the first high-resolution structure of a vertebrate Cu+-ATPase, which delineates the shared and distinct features
among Cu+-ATPases and provides a molecular blueprint for further understanding numerous Wilson disease mutations. The Cu+-
ATPases from eukaryotes and prokaryotes share a core structure
consisting of the A, P, and N domains and a P1B-specific TMD with
eight TM helices (Fig. 5). In contrast to prokaryotic Cu+-ATPases,
the eukaryotic counterparts contain a greater number of N-terminal
MBDs and an extended C-terminal tail. These extra structural
Bitter et al., Sci. Adv. 8, eabl5508 (2022)
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components surround the conserved cytosolic headpieces of the
Cu+-ATPase apparatus and form extensive interdomain packing
interactions. Both the N-terminal MBDs and C-terminal tail appear
to be strategically positioned to exert additional regulatory roles
by interfering with conformational changes in cytosolic headpieces,
which are necessary for coupling ATP hydrolysis to TMD movements that facilitate active Cu+ transport across the membrane.
Furthermore, structural organization of these domains indicates
that the regulatory roles are poised to be modulated by Cu+ binding to MBDs.
The arrangement of TM helices is conserved between prokaryotic
and eukaryotic Cu+-ATPases (root mean square deviation of the C
atoms between eight TM helices is ~1.6 Å). Mapping of potential
Cu + ligands in the TMD, including cysteine, methionine, and
charged amino acids, suggests a similar stepwise shuttle mechanism
for Cu+ transport as well as an analogous “platform” entry site to
accommodate the N-terminal MBDs or a cytosolic chaperone for
Cu + transfer (Fig. 5 and fig. S5) (12). Presumably, structural
rearrangements, associated with Cu+ loading to the MBDs and
ATPase activity in the cytosolic domains, drive unidirectional Cu+
movement from the cytosolic entry site through the intramembranous binding sites and to the luminal side. Notably, the wide exit
tunnel to the lumen observed in the presumed E2-Pi state supports
a unique ion-release mechanism for Cu+-ATPases as previously
suggested (13). The Cu+-coordinating amino acids seem to be
delicately arranged within the membrane to relay Cu+ via ligand
exchange reactions. In comparison with the prokaryotic Cu+-ATPases,
the eukaryotic counterparts constitute a more refined transmembrane Cu+ path that involves additional Cu+-binding amino acids
such as M766 and M668 (Fig. 5). Notably, the eukaryotic ATP7
transporters have evolved to engage a conserved basic residue R775,
which corresponds to glutamine at the equivalent position in LpCopA
(fig. S1), as the cytoplasmic gatekeeper for Cu+ entry. Coincidently,
an amino acid substitution at this position in human ATP7B (R778L)
gives rise to a prevalent Wilson disease mutation (8, 34).
MATERIALS AND METHODS

Cloning, expression, and purification of ATP7B
DNA encoding X. tropicalis ATP7B was codon-optimized, synthesized
(Bio Basic), and served as the template for subcloning. Deletion of
the N-terminal 480 amino acids corresponding to MBD1 to MBD4
(xATP7BEM) improved biochemical stability and decreased protein
degradation and thus was suitable for structural studies. DNA
was polymerase chain reaction–amplified and ligated into the 5′
Xho I and 3′ Eco RI cloning sites of a modified pPICZ-B vector
(Invitrogen) under a methanol-inducible promoter. The expression construct contains a C-terminal PreScission protease cleavage
site linked to a green fluorescent protein (GFP)–His10 tag. The plasmid
was linearized by Pme I and transformed into Pichia pastoris for
expression.
Yeast cells were disrupted by milling (Retsch MM400) and resuspended in lysis buffer containing 50 mM Hepes (pH 7.0), 150 mM
NaCl, 5 mM MgCl2, 0.5 mM adenosine 5′-diphosphate (ADP),
10 mM NaF, and 1 mM AlCl3 supplemented with protease inhibitors [leupeptin (2.5 g/ml), pepstatin A (1 g/ml), 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride (100 g/ml), aprotinin
(3 g/ml), 1 mM benzamidine, and 200 M phenylmethylsulfonyl
fluoride] and deoxyribonuclease I. Cell membranes were solubilized
7 of 10

Downloaded from https://www.science.org at Washington University on June 05, 2022

of the C-terminal sites. The xATP7BEM structure provides direct
evidence that the N and C termini physically interact and thus
offers a straightforward explanation for the observed long-range
cross-talk between the N and C termini. To further probe the
functional role of the C-terminal tail, we removed this portion
beginning at K1384, and the resulting construct (xATP7BC)
essentially eliminated the ATPase activity (Fig. 1B). In accordance
with previous studies (44), our structural and functional data
demonstrated the obligatory role of the C-terminal tail that is
unique in eukaryotic Cu+-ATPases. In contrast, in P4-ATPases, an
analogous C-terminal tail wraps around the cytosolic headpieces
to confer an autoinhibitory role by blocking ATP binding and
constricting domain movement (45–47).
In addition to a conserved Cu+-ATPase core, our vertebrate
ATP7B structure reveals previously unknown structural elements at
both the N and C termini (Fig. 3). To further validate these structural
observations, we introduced mutations in the N-terminal MBD5
(L520A/M521A) and MBD6 (R613E) domains and the C-terminal
tail (K1384E) on the xATP7BEM background, which presumably
weaken domain-domain interactions with the catalytic core, and measured the ATPase activity (Fig. 3G). Consistently, all these mutants
demonstrated a reduced ATP turnover rate, thus indicating the involvement of these structural elements in regulation of transport activity
through interactions with the cytosolic headpieces. Notably, the
charge reversal mutation (K1384E) in the C-terminal tail resulted
in the most pronounced reduction of the ATP turnover rate.
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Cryo-EM sample preparation and imaging
Four microliters of purified xATP7BEM protein at ~7 mg ml−1 was
added to Au 400 mesh Quantifoil R1.2/1.3 holey carbon grids
(Quantifoil) that had been glow-discharged for 60 s. After a 20-s
incubation, the grids were blotted for 2 s with a blot force of 0 and
rapidly plunged into liquid nitrogen–cooled liquid ethane using a
FEI Vitrobot Mark IV (FEI Thermo Fisher Scientific). A total of
3439 images were recorded in super-resolution mode at a nominal
margination of 22,500× on a Titan Krios (Thermo Fisher Scientific)
operating at 300 kV equipped with a K2 Summit (Gatan). The calibrated super-resolution pixel size was 0.544 Å/pixel. The dose rate
was eight electrons per pixel per second for 8 s using 0.2-s frames,
and images were acquired with a defocus range of −1.2 to −2.5 m
using SerialEM (49).
Image processing and map calculation
The super-resolution movies were gain-corrected, Fourier-cropped
to a pixel size of 1.088 Å/pixel, and aligned using whole frame and
local motion correction using MotionCor2 (50). Contrast transfer function (CTF) parameters were estimated using CTFFIND 4.1.10 (51).
Particles were automatically selected using Laplacian of Gaussian
autopicking in Relion 3.0 (52). False-positive selections were eliminated using iterative heterogeneous classification in cryoSPARC v3
(53) using models generated from the ab initio algorithm in cryoSPARC
v3. After Bayesian polishing in Relion and global and local CTF refinement in cryoSPARC v3, the consensus refinement from 257,208
particles achieved a resolution of 3.19 Å using nonuniform refinement in
cryoSPARC v3 (54). 3DVA in cryoSPARC revealed the presence of
two distinct states, one in which MBD5 and MBD6 were resolved
(state 1) and one in which the density for MBD5 and MBD6 was
absent (state 2). Heterogeneous classification using the maps generated by 3DVA yielded a stack of 138,790 particles for state 1 and
118,418 particles for state 2, which achieved resolutions of 3.32 and
3.49 Å, respectively. All reconstructions were subsequently subjected to density modification in Phenix using a soft mask (55).
Bitter et al., Sci. Adv. 8, eabl5508 (2022)
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Model building and coordinate refinement
The structure of LpCopA (PDB: 3RFU) was manually docked into
the density modified consensus map in UCSF Chimera (56) and
then rebuilt in Coot (57). The structure of human MBD4 (PDB:
6A71) was docked in the densities corresponding to MBD5 and
MDB6 in state 1 using UCSF Chimera and then rigid-body fit and
manually rebuilt in Coot (32). The manually built models were
refined in ISOLDE (58) and by using real-space refinement in
Phenix with geometric and Ramachandran restraints (59). The
refined consensus model was docked into the state 2 structure, and
the missing MBDs were removed from the model before real space
refinement in Phenix.
ATPase assay
All xATP7B constructs used in the ATPase assay were expressed
and purified following the procedure described for xATP7BEM,
except that NaF and AlCl3 were removed in the lysis and wash
buffers, and the gel filtration buffer contained 20 mM Hepes (pH 7.0),
150 mM NaCl, and 40 M GDN. Peak fractions were collected and
concentrated to ~1 to 2 mg ml−1 for the ATPase assay. Concentrated
protein was immediately flash-frozen and stored in −80°C until
further usage. ATPase activity was measured using Bismuth detection method (12, 60). Measurements were conducted with equal
amounts of protein (1 M) for each construct. In a total reaction
volume of 50 l, protein was mixed with the ATPase assay buffer
[40 mM Mops-KOH (pH 6.8), 150 mM NaCl, 5 mM KCl, 5 mM
MgCl2, 20 mM (NH4)2SO4, 20 mM cysteine, 5 mM NaN3, 0.25 mM
Na2MoO4, and 80 M GDN]. Ammonium tetrathiomolybdate
(TTM; 10 M) was added to each reaction mix to eliminate free
copper. An increasing amount of ATP was added to initiate the
reaction, and the mixture was incubated at 37°C for 15 min. Reactions
were stopped by addition of 75 l of freshly made quench solution
[2.86% ascorbic acid, 1 M HCl, 0.48% (NH4)2MoO4, and 2.86% SDS]
and then incubated at room temperature for 8 min. Last, 125 l of
stabilizing solutions (3.5% bismuth citrate, 1 M HCl, and 3.5% sodium
citrate) was added to the mixture and incubated for 30 min at room
temperature. Absorbance was measured at 710 nm using Cytation 5
(BioTek) plate reader. The background from blank (assay buffer
with TTM) was subtracted from each data point to retrieve the
actual reads. The amount of inorganic phosphate released was
determined by using the K2HPO4 standard as described previously
(60). All measurements were performed in three replicates. The
kinetic parameters were deduced from the Michaelis-Menten
equation using Prism (www.graphpad.com). We have not been able
to establish in vitro Cu+-stimulated ATPase activity, because the
purified frog ATP7B protein was prone to aggregation with the
addition of Cu+.
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abl5508
View/request a protocol for this paper from Bio-protocol.
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